Sung Lee: Well, if you look at last year, it was above 30 — on an operating cash burn basis, it’s over €30 million per month. Now, I would expect this year to be somewhat at similar levels and maybe even slightly lower. But the important thing here is, with our €907 million at the end of last year, this gets us well past the pivotal data for pelabresib. And in fact, I mentioned in my prepared comments, we expect to have at least 12 months of cash post the pivotal data for pela. I think the way to look at this is, when we get to that inflection point, the pela data readout, and if it’s positive, which we believe it can be, I think we will have good options to consider. So, I think that should be the focus right now is we have ample cash, more than enough to get through that inflection point, and then we’ll think about we’ll deal with the options at that point.
Suzanne van Voorthuizen: All right. Thanks a lot.
Operator: Madam, gentlemen so further are no more questions from the phone. We have a question right now from Mohamad Vaseghi from Frankfurt Main Research. Please go ahead.
Mohamad Vaseghi: Thank you that you’re taking my questions, so maybe I missed it. So, I have just one question. With the Phase 3 MANIFEST-2 study expected to report topline data in early 2024. Can you provide any updates on the progress of this trial, and what potential impact this data could have on the future of the MorphoSys pipeline and strategy? Thank you.
Jean-Paul Kress: Mohamad, thank you for the question. This is Jean-Paul. This MANIFEST-2 study is our pivotal study as you probably know, on our main asset pelabresib. And it’s so far our largest opportunity for one, challenging the standard-of-care in myelofibrosis and one I would say, value creation. So, this is really an extremely important study for us. And so far, so good. As we mentioned several times, we have execute — we have been executing in a very swift pace. We’ve advanced the date of the topline results to early 2024, as you just mentioned. And again, the demand from the study, from the space, from the investigators has been very, very high. So, all is on the green for this one, which is full blast on execution, continuing to balance the speed versus quality. And we are now in this less than 12 month window. So, super important for us, but super exciting and we are very, very excited by the potential outcome for our patients and the company.
Mohamad Vaseghi: Thank you. Just very short question. So, do you see any kind of the portfolio focused on prioritization? Like, how is the company actually prioritizing its development pipeline and allocating the resources to different programs, something like that?
Jean-Paul Kress: Yeah. We’ve already done that. We passed that. Sung said that in his comments on the expenses allocation. I mean, we’ve really reprioritized or prioritized towards these late stage programs and namely the pelabresib program and the MANIFEST-2 trial. We’ve made this — we’ve taken these difficult decisions to end earlier discovery stage programs and operations. And so that prioritization is operated. Now we continue with no complacency to look at our cost base, but it’s already — we cost — replica on this one. First of all, because our study is very clear to our late stage pipeline and opportunities, but also because we’ve executed and implemented to us that we walk and talk.
Mohamad Vaseghi: Thank you so much, was helpful.
Mohamad Vaseghi: Thank you.
Operator: There are no further questions at this time. I would now like to hand the conference back over to Julia Neugebauer for any closing comments. Thank you.
End of Q&A:
Julia Neugebauer: Ladies and gentlemen, this concludes today’s conference call. If any of you would like to follow up investor relations team of MorphoSys is available for the remainder of the day. Once again, thank you for joining our call. Have a good day and goodbye.
Operator: Ladies and gentlemen, the conference is now concluded and you may disconnect.
